Bayer applies to market VTE drug in Europe
Bayer HealthCare unit has submitted an application for European marketing rights of its drug Rivaroxaban, a drug aimed at preventing venous thromboembolism (VTE) after major orthopedic surgery of the lower limbs.
Bayer reported that it expects its annual peak sales of the oral, once-a-day drug to exceed $2.89 billion.
Rivaroxaban is one of the most important drugs in Bayer’s pharma pipeline, according to Ulle Woerner, analyst from Landesbank Baden-Wuerttemberg.
The drug, which Bayer jointly developed with Johnson & Johnson, is also being examined for chronic treatment of thrombosis.
Bayer is still awaiting regulatory approval in Europe.
A similar U.S. filing for Rivaroxaban is scheduled in 2008, where, if approved, it will be marketed by Scios and Ortho-McNeil, both of which are Johnson & Johnson companies.
Bayer reported that it expects its annual peak sales of the oral, once-a-day drug to exceed $2.89 billion.
Rivaroxaban is one of the most important drugs in Bayer’s pharma pipeline, according to Ulle Woerner, analyst from Landesbank Baden-Wuerttemberg.
The drug, which Bayer jointly developed with Johnson & Johnson, is also being examined for chronic treatment of thrombosis.
Bayer is still awaiting regulatory approval in Europe.
A similar U.S. filing for Rivaroxaban is scheduled in 2008, where, if approved, it will be marketed by Scios and Ortho-McNeil, both of which are Johnson & Johnson companies.